Limiting Skeletal Risks in Breast Cancer

Submitted by admin5 on Thu, 11/02/2017 - 16:09

According to a recent study, which therapy is most cost-effective for reducing the risk of skeletal events in breast cancer?



A. Denosumab every month

B. Zoledronic acid every 3 months

C. Denosumab every 3 months

D. Zoledronic acid every month


To see the correct answer, click here.


Related Content

Novel Immunotherapy Improves Survival in Advanced Breast Cancer

Prognosis Is Improving for Younger Breast Cancer Patients After Breast-Conserving Surgery